KGX 101
Alternative Names: KGX-101Latest Information Update: 19 Jun 2024
Price :
$50 *
At a glance
- Originator KangaBio
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 04 Nov 2023 Clinical trials in Solid tumours (Late-stage disease, Combination therapy) in Australia (IV)
- 04 Nov 2023 Clinical trials in Solid tumours (Late-stage disease, Monotherapy) in Australia (IV) (NCT06074497)